Patents by Inventor Ryohei MAGARA

Ryohei MAGARA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-HYDROXYOXINDOLE DERIVATIVES AS CRHR2 ANTAGONIST
    Publication number: 20240018103
    Abstract: The present invention relates to 3-hydroxyoxindole derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR2 is involved.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 18, 2024
    Applicant: RaQualia Pharma Inc.
    Inventors: Kazuo ANDO, Masashi OHMI, Ryohei MAGARA
  • Fused cyclic urea derivatives as CRHR2 antagonist
    Patent number: 11802120
    Abstract: The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 31, 2023
    Assignee: RaQualia Pharma Inc.
    Inventors: Masashi Ohmi, Takeshi Matsushita, Kazuo Ando, Ryuichi Yamaguchi, Yutaka Fukumoto, Ryohei Magara, Tatsuya Yamagishi, Mikito Takefuji
  • PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS
    Publication number: 20230339934
    Abstract: This invention relates to pyrimidin-4(3H)-one derivatives that act as modulators of the TRPV4 receptor. The present invention also relates to processes for the preparation of novel pyrimidin-4(3H)-one derivatives and to their use in the treatment of a wide range of diseases, syndromes, and disorders, in particular for the treatment of inflammatory, pain, and urological diseases or disorders.
    Type: Application
    Filed: April 30, 2021
    Publication date: October 26, 2023
    Applicant: RaQualia Pharma Inc.
    Inventors: Yuji SHISHIDO, Tadashi INOUE, Tatsuya YAMAGISHI, Kazuo ANDO, Yutaka FUKUMOTO, Ryohei MAGARA
  • FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
    Publication number: 20210078975
    Abstract: The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.
    Type: Application
    Filed: April 9, 2019
    Publication date: March 18, 2021
    Applicants: RaQualia Pharma Inc., National University Corporation Tokai National Higher Education and Research System
    Inventors: Masashi OHMI, Takeshi MATSUSHITA, Kazuo ANDO, Ryuichi YAMAGUCHI, Yutaka FUKUMOTO, Ryohei MAGARA, Tatsuya YAMAGISHI, Mikito TAKEFUJI